Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662909 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,149
- Enrollment target
NCT00662909 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 2,149 participants.
The verdict
NCT00662909, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,149 participants
- Enrollment target
Study Summary
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,149 participants |
| Start Date | 2008-03-28 |
| Est. Completion | 2009-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662909
The ClinicalTrials.gov registry entry for NCT00662909 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00662909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662909 about?
NCT00662909 is a clinical study titled "A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder". The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
What is the current status of trial NCT00662909?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,149 participants. The study started on 2008-03-28. Estimated completion is 2009-04-22.
What interventions are being tested in trial NCT00662909?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT00662909?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.